Biofrontera Inc. is a biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy and topical antibiotics. The Company's licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Biofrontera Inc. is based in WOBURN, MA.
| Revenue (Most Recent Fiscal Year) | $41.71M |
| Net Income (Most Recent Fiscal Year) | $-10.54M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.31 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.22 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -25.20% |
| Net Margin (Trailing 12 Months) | -25.26% |
| Return on Equity (Trailing 12 Months) | -1236.11% |
| Return on Assets (Trailing 12 Months) | -56.67% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.52 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.40 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.44 |
| Inventory Turnover (Trailing 12 Months) | 2.69 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.90 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.50 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.20 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.03 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 11.65M |
| Free Float | 11.09M |
| Market Capitalization | $12.81M |
| Average Volume (Last 20 Days) | 0.12M |
| Beta (Past 60 Months) | 0.63 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 10.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |